Roche’s Susvimo, for `wet’ age-related macular degeneration (nAMD) approved

The implant is surgically inserted into the eye during a one-time, outpatient procedure and refilled every six months

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients

Univar Solutions bags exclusive US & Canada deal for Ingredion Pharmaceutical starches

Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D

The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform

Bayer introduces chemo-free treatment option for advanced prostate cancer in India

Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year

Lupin receives European Commission approval for biosimilar Ranibizumab

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar

Iambic taps AI to power multi-year drug discovery deal with Takeda

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike